Home » Topics » BioWorld Science

BioWorld Science
RSS

Orphan drug status for CEA-Scan

May 24, 1996

Peptide Therapeutics, Dr. Fooke to research arthritis diagnostics

May 24, 1996

Isis claims oligonucleotides for diagnostic use

May 24, 1996

Atrix completes phase III studies of Atridox

May 24, 1996

PolyHeme phase II results in trauma patients announced

May 24, 1996

RF-1051 receives orphan drug status in PWS

May 24, 1996

Amgen begins clinical testing of leptin

May 24, 1996

Intrachol receives U.S. patent protection

May 24, 1996

Orphan Medical discontinues glucaric acid development

May 24, 1996

Zoledronate effective in Paget's disease patients

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.